Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies.
about
Supportive care for patients undergoing immunotherapy.Blocking the VISTA pathway enhances disease progression in (NZB × NZW) F1 female mice.Basal cell carcinoma pathogenesis and therapy involving hedgehog signaling and beyond.Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors.Safety and efficacy of nivolumab in the treatment of cancers: A meta-analysis of 27 prospective clinical trials.Development of Papulopustular Rosacea during Nivolumab Therapy for Metastatic CancerNivolumab-associated vitiligo-like depigmentation in a patient with acute myeloid leukemia: A novel findingAdverse Events in Cancer Immunotherapy.Review: Metabolic Control of Immune System Activation in Rheumatic Diseases.Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.Diverse cutaneous adverse eruptions caused by anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) immunotherapies: clinical features and management.PD-L1 reverses depigmentation in Pmel-1 vitiligo mice by increasing the abundance of Tregs in the skin.Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors.A case report of disappearing pigmented skin lesions associated with pembrolizumab treatment for metastatic melanoma.Lichen planopilaris associated with pembrolizumab in a patient with metastatic melanoma.[Initially undetected de novo psoriasis triggered by nivolumab for metastatic base of the tongue carcinoma].Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.When worlds collide: Th17 and Treg cells in cancer and autoimmunity.Drug-induced psoriasis: clinical perspectives.Oral lichenoid reactions associated with anti-PD-1/PD-L1 therapies: clinicopathological findings.Two cases of anti-programmed cell death 1-associated bullous pemphigoid-like disease and eruptive keratoacanthomas featuring combined histopathology.Psoriasiform eruption on the face and extremities associated with nivolumab therapy.Clinical assessment of immune-related adverse events.Management of Persistent Pruritus and Lichenoid Reaction Secondary to Nivolumab With Narrowband Ultraviolet B PhototherapyDe Novo Psoriasis Vulgaris Diagnosed after Nivolumab Treatment for Refractory Hodgkin's Lymphoma, Completely Resolved after Autologous Hematopoietic Stem Cell TransplantationDecreased blood CD4+PD-1+ and CD8+PD-1+ T cells in psoriatic patients with and without arthritisAtezolizumab-Induced Stevens-Johnson Syndrome in a Patient with Non-Small Cell Lung CarcinomaPsoriasis Vulgaris Exacerbation during Treatment with a PD-1 Checkpoint Inhibitor: Case Report and Literature Review
P2860
Q38679728-E82CD516-57B6-4261-8951-4AA06613850BQ38704089-C68E4953-DCAD-4FE2-B734-9741E80C4E58Q38748824-981DFD1E-4B36-472F-83B9-F833BF5F5C93Q38948950-BCF8BD92-BE3D-40CC-BD86-7BA5ED0F9059Q39215902-6B2D9F22-C2E3-4551-AF30-2873687DA76BQ41273211-D9915235-8F36-49EF-AC78-D2A6022F5B53Q42065866-CA3423C1-A99C-491D-AA45-28B3E95BE4F3Q46884498-A96CAF0B-F11B-47EE-B004-89161EA45658Q47133379-D97C5465-3181-41DD-A5DB-A49CBD52F0CDQ47277879-427C3E55-86D2-45F5-AEDA-51000CDE5C6EQ48138293-62CDDB2B-EC1C-4C95-85FF-F84A6BB78DC3Q48162560-1547191F-8F73-49CF-9F95-95A5F338433CQ48164354-C00BB222-3F92-488D-B27D-C88F0A76A58FQ48301194-1B93BEA0-49C7-4E97-ACD3-6566A7E33B77Q49294620-CE0D5400-F6E5-420E-BB21-63BC86CE1B82Q50058093-F967F1EC-A92B-4775-8327-B3A0653A372FQ50205173-0E026D1A-A146-4600-A26A-C1BBB5017F7DQ52689973-35705134-2E3F-4EAE-BB4E-7F064F5EF3DBQ52701370-294401F2-EC70-4A3A-9303-158443CAA65BQ53836578-41A30235-325D-462F-B13C-7F3EFC65F9A1Q54756013-ADB937A1-4F4F-490B-AFB1-1B491EB94396Q55022441-EAC81756-5C5F-42D5-89E1-7BA86883BDD7Q55292659-BC342EE0-32F1-445E-92E1-F3D907AC202FQ57492116-B7268402-F81E-4676-BCC8-F2A3DB1EDB6EQ58551824-40802F35-DD1D-4089-ABCF-6E5E4F3E33EBQ58727230-40278E0C-33A4-4A6E-90A1-2331A894333AQ58792536-F9351096-9BCA-4DFE-8301-C18A17CF4E0EQ58792541-D7AD5E8B-DE22-4032-9B5E-EAF02185236F
P2860
Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies.
@en
type
label
Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies.
@en
prefLabel
Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies.
@en
P2093
P1476
Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies.
@en
P2093
Emmanuelle Vigarios
Jean Pierre Delord
Laurence Lamant
Vincent Sibaud
P304
P356
10.1097/CCO.0000000000000290
P577
2016-04-28T00:00:00Z